| Margins | Targeting 15.5% to 18% EBITDA margins across different business segments. |
|---|---|
| Order book | Good order book reported in Prague nutraceutical venture. |
| Demand visibility | Steady inquiries and consistent demand across key product categories and geographies. |
| Management confidence | High optimism for FY27 across all three business verticals. |
Growth
Q4 Consolidated Revenue ₹132.1M; PAT ₹5.5M (3.97% margin). Standalone Revenue ₹105.1M; EBITDA ₹16.58M (14.7% margin).
Outlook
FY27 guidance: Base business ₹80-85cr, Pune IVF plant ₹60-65cr. Targeted EBITDA margins 15.5-16.5% (base) and 17-18% (IVF).
Risks
Geopolitical tensions in Middle East disrupted March exports; rising raw material (API/packaging) and logistics costs.
Earnings Call filed with BSE, NSE: SANJIVIN. Summary written with AI assistance from the document.
Sanjivani Paranteral Ltd: key numbers
- Share price
- ₹179.85
- Market cap
- ₹220.9 Cr
- Revenue (annual)
- ₹68.67 Cr
- Net profit (annual)
- ₹6.79 Cr
- P/E (TTM)
- 21.0×Sector 47.4×
- Promoter holding
- 31.56%+0.30% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanjivani Paranteral Ltd
All →Sanjivani Paranteral Fund Raise
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Annual Report
Sanjivani Paranteral Limited has filed its Annual Report for the financial year 2025-26 as required under SEBI regulations. The document details the company's annual performance.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral shareholders approved the issuance of 5,00,000 convertible warrants to promoters on a preferential basis. A material related party transaction with subsidiary SPL Infusion was also cleared.
Sanjivani Paranteral Results Update
Sanjivani Paranteral reported Q1 FY27 results, with total income of ₹23.99 Crore and a net profit of ₹2.49 Crore. The company demonstrated strong year-on-year growth across key metrics.
Sanjivani Paranteral Investor Presentation: Key Takeaways
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
- Call
- Guides 110% growth